Cancer and leukemia group B pathology committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues

David L. Rimm, Torsten O. Nielsen, Scott D. Jewell, Daniel C. Rohrer, Gloria Broadwater, Frederic Waldman, Kisha A. Mitchell, Baljit Singh, Gregory J. Tsongalis, Wendy L. Frankel, Anthony M. Magliocco, Jonathan F. Lara, Eric D. Hsi, Ira J. Bleiweiss, Sunil S. Badve, Beiyun Chen, Peter M. Ravdin, Richard L. Schilsky, Ann Thor, Donald A. Berry

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Practice-changing evidence requires confirmation, preferably in multi-institutional clinical trials. The collection of tissue within such trials has enabled biomarker studies and evaluation of companion diagnostic tests. Tissue microarrays (TMAs) have become a standard approach in many cooperative oncology groups. A principal goal is to maximize the number of assays with this precious tissue. However, production strategies for these arrays have not been standardized, possibly decreasing the value of the study. In this article, members of the Cancer and Leukemia Group B Pathology Committee relay our experiences as array facility directors and propose guidelines regarding the production of high-quality TMAs for cooperative group studies. We also discuss statistical issues arising from having a proportion of patients available for TMAs and the possibility that patients with TMAs fail to represent the greater study population.

Original languageEnglish (US)
Pages (from-to)2282-2290
Number of pages9
JournalJournal of Clinical Oncology
Volume29
Issue number16
DOIs
StatePublished - Jun 1 2011

Fingerprint

Leukemia
Clinical Trials
Guidelines
Pathology
Neoplasms
Routine Diagnostic Tests
Biomarkers
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cancer and leukemia group B pathology committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues. / Rimm, David L.; Nielsen, Torsten O.; Jewell, Scott D.; Rohrer, Daniel C.; Broadwater, Gloria; Waldman, Frederic; Mitchell, Kisha A.; Singh, Baljit; Tsongalis, Gregory J.; Frankel, Wendy L.; Magliocco, Anthony M.; Lara, Jonathan F.; Hsi, Eric D.; Bleiweiss, Ira J.; Badve, Sunil S.; Chen, Beiyun; Ravdin, Peter M.; Schilsky, Richard L.; Thor, Ann; Berry, Donald A.

In: Journal of Clinical Oncology, Vol. 29, No. 16, 01.06.2011, p. 2282-2290.

Research output: Contribution to journalArticle

Rimm, DL, Nielsen, TO, Jewell, SD, Rohrer, DC, Broadwater, G, Waldman, F, Mitchell, KA, Singh, B, Tsongalis, GJ, Frankel, WL, Magliocco, AM, Lara, JF, Hsi, ED, Bleiweiss, IJ, Badve, SS, Chen, B, Ravdin, PM, Schilsky, RL, Thor, A & Berry, DA 2011, 'Cancer and leukemia group B pathology committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues', Journal of Clinical Oncology, vol. 29, no. 16, pp. 2282-2290. https://doi.org/10.1200/JCO.2010.33.2023
Rimm, David L. ; Nielsen, Torsten O. ; Jewell, Scott D. ; Rohrer, Daniel C. ; Broadwater, Gloria ; Waldman, Frederic ; Mitchell, Kisha A. ; Singh, Baljit ; Tsongalis, Gregory J. ; Frankel, Wendy L. ; Magliocco, Anthony M. ; Lara, Jonathan F. ; Hsi, Eric D. ; Bleiweiss, Ira J. ; Badve, Sunil S. ; Chen, Beiyun ; Ravdin, Peter M. ; Schilsky, Richard L. ; Thor, Ann ; Berry, Donald A. / Cancer and leukemia group B pathology committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues. In: Journal of Clinical Oncology. 2011 ; Vol. 29, No. 16. pp. 2282-2290.
@article{7ebc662d5782434fb0dd49429b8f4d8b,
title = "Cancer and leukemia group B pathology committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues",
abstract = "Practice-changing evidence requires confirmation, preferably in multi-institutional clinical trials. The collection of tissue within such trials has enabled biomarker studies and evaluation of companion diagnostic tests. Tissue microarrays (TMAs) have become a standard approach in many cooperative oncology groups. A principal goal is to maximize the number of assays with this precious tissue. However, production strategies for these arrays have not been standardized, possibly decreasing the value of the study. In this article, members of the Cancer and Leukemia Group B Pathology Committee relay our experiences as array facility directors and propose guidelines regarding the production of high-quality TMAs for cooperative group studies. We also discuss statistical issues arising from having a proportion of patients available for TMAs and the possibility that patients with TMAs fail to represent the greater study population.",
author = "Rimm, {David L.} and Nielsen, {Torsten O.} and Jewell, {Scott D.} and Rohrer, {Daniel C.} and Gloria Broadwater and Frederic Waldman and Mitchell, {Kisha A.} and Baljit Singh and Tsongalis, {Gregory J.} and Frankel, {Wendy L.} and Magliocco, {Anthony M.} and Lara, {Jonathan F.} and Hsi, {Eric D.} and Bleiweiss, {Ira J.} and Badve, {Sunil S.} and Beiyun Chen and Ravdin, {Peter M.} and Schilsky, {Richard L.} and Ann Thor and Berry, {Donald A.}",
year = "2011",
month = "6",
day = "1",
doi = "10.1200/JCO.2010.33.2023",
language = "English (US)",
volume = "29",
pages = "2282--2290",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "16",

}

TY - JOUR

T1 - Cancer and leukemia group B pathology committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues

AU - Rimm, David L.

AU - Nielsen, Torsten O.

AU - Jewell, Scott D.

AU - Rohrer, Daniel C.

AU - Broadwater, Gloria

AU - Waldman, Frederic

AU - Mitchell, Kisha A.

AU - Singh, Baljit

AU - Tsongalis, Gregory J.

AU - Frankel, Wendy L.

AU - Magliocco, Anthony M.

AU - Lara, Jonathan F.

AU - Hsi, Eric D.

AU - Bleiweiss, Ira J.

AU - Badve, Sunil S.

AU - Chen, Beiyun

AU - Ravdin, Peter M.

AU - Schilsky, Richard L.

AU - Thor, Ann

AU - Berry, Donald A.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Practice-changing evidence requires confirmation, preferably in multi-institutional clinical trials. The collection of tissue within such trials has enabled biomarker studies and evaluation of companion diagnostic tests. Tissue microarrays (TMAs) have become a standard approach in many cooperative oncology groups. A principal goal is to maximize the number of assays with this precious tissue. However, production strategies for these arrays have not been standardized, possibly decreasing the value of the study. In this article, members of the Cancer and Leukemia Group B Pathology Committee relay our experiences as array facility directors and propose guidelines regarding the production of high-quality TMAs for cooperative group studies. We also discuss statistical issues arising from having a proportion of patients available for TMAs and the possibility that patients with TMAs fail to represent the greater study population.

AB - Practice-changing evidence requires confirmation, preferably in multi-institutional clinical trials. The collection of tissue within such trials has enabled biomarker studies and evaluation of companion diagnostic tests. Tissue microarrays (TMAs) have become a standard approach in many cooperative oncology groups. A principal goal is to maximize the number of assays with this precious tissue. However, production strategies for these arrays have not been standardized, possibly decreasing the value of the study. In this article, members of the Cancer and Leukemia Group B Pathology Committee relay our experiences as array facility directors and propose guidelines regarding the production of high-quality TMAs for cooperative group studies. We also discuss statistical issues arising from having a proportion of patients available for TMAs and the possibility that patients with TMAs fail to represent the greater study population.

UR - http://www.scopus.com/inward/record.url?scp=79957958114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957958114&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.33.2023

DO - 10.1200/JCO.2010.33.2023

M3 - Article

VL - 29

SP - 2282

EP - 2290

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 16

ER -